Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio
December 06, 2024 07:30 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
December 04, 2024 08:00 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
October 21, 2024 07:30 ET | Source: Elevai Labs Inc.

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
October 03, 2024 15:45 ET | Source: Elevai Labs Inc.

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
September 10, 2024 07:30 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
August 28, 2024 07:30 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria
August 14, 2024 09:05 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
July 30, 2024 09:00 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
June 28, 2024 09:00 ET | Source: Elevai Labs Inc.

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

Next Page keyboard_arrow_right